On August 30, 2021 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported that the company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually from September 13-15, 2021 (Press release, Kineta, AUG 30, 2021, https://kinetabio.com/2021/08/30/hc-wainwright-conference/?utm_source=rss&utm_medium=rss&utm_campaign=hc-wainwright-conference [SID1234587001]). Shawn Iadonato, PhD, Chief Executive Officer of Kineta will present a corporate overview, that will be viewable online. Members of the management team will also be available for virtual meetings with institutional investors throughout the course of the conference. For more information on the conference or to register, visit: HCW Events.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!